Has ibrutinib been funded by Pharmac for the treatment of relapsed or refractory mantle cell lymphoma; and if not, is it under consideration for funding?

Answer

No, ibrutinib is not currently funded by Pharmac for the treatment of relapsed or refractory mantle cell lymphoma. I am advised by Pharmac that ibrutinib has been assessed and added to the Options for Investment List, and may be considered for funding should sufficient budget become available. I refer the Member to the following link for more information: https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puXu/p001189